Explore / Peer-reviewed article
Peer-reviewed article

Ethical Concerns about Psilocybin Intellectual Property.

Gerber K, Flores IG, Ruiz AC, Ali I, Ginsberg NL, Schenberg EE

ACS pharmacology & translational scienceJan 1, 2021Brazil, Mexico, Switzerland, United States26 citationsDOI: 10.1021/acsptsci.0c00171

Abstract

Since a 1957 exposé in Life Magazine, chemical compounds derived from Psilocybe mushrooms have been the focus of dozens of attempted and successful patents, most recently to treat depression. Regrettably, the Mazatec indigenous communities who stewarded these traditional medicines for millenia are not party to any of these patents, despite a number of international treaties asserting indigenous rights to their intangible cultural heritage.

Topics & conditions

Detected automatically by Psychedelic Commons from the title and abstract, not labels from the source. They may be incomplete.

PsilocybinDepression

Psychedelic Commons aggregates metadata from open sources and links back to the original. Rights remain with the authors and publishers. Something wrong with this record? Report a problem.